US2018327502A1PendingUtilityA1
BINDING MEMBERS OF INTERLEUKIN-4 RECEPTOR ALPHA (IL4-Ra)
Est. expiryDec 21, 2027(~1.4 yrs left)· nominal 20-yr term from priority
Inventors:Per-Olof ErikssonKarin Von WachenfeldtEmma Suzanne CohenClaire Louise DobsonDeborah Louise Lane
A61P 37/06A61P 37/08A61P 29/00C07K 2317/92A61P 1/00C07K 2317/56C07K 2317/567C07K 2317/21C07K 16/2866C07K 2319/32C07K 2317/76C07K 2317/515C07K 2319/30C07K 2317/622C07K 2317/565C07K 2317/51C07K 2317/73A61P 11/06
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4Rα), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4Rα, IL-4 and/or IL-13, examples of which are asthma and COPD.
Claims
exact text as granted — not AI-modified1 . An isolated antibody or fragment thereof that specifically binds an epitope on human interleukin-4 receptor alpha (hIL-4Rα), wherein the epitope comprises L67 and L68 of loop 2 and D92 and V93 of loop 3 according to SEQ ID NO: 460.
2 . The isolated antibody or fragment of claim 1 , wherein the epitope comprises amino acid residues within V65-H72 of loop 2 and L89-N98 of loop 3 according to SEQ ID NO: 460 or a portion thereof.
3 . The isolated antibody or fragment of claim 1 , wherein the antibody molecule is an IgG1, IgG2 or IgG4 molecule.
4 . An isolated antibody or fragment thereof that specifically binds to an epitope on human interleukin-4 receptor alpha (hIL-4Rα), wherein the epitope comprises amino acid residues V65-H72 and L89-N98 of SEQ ID NO: 460.
5 . The isolated antibody or fragment of claim 4 , wherein the isolated antibody or fragment thereof cross-reacts with cynomolgous monkey IL-4Rα.
6 . The isolated antibody or fragment of claim 4 , wherein the isolated antibody is an IgG1, IgG2 or IgG4 molecule.Join the waitlist — get patent alerts
Track US2018327502A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.